{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:15:13Z","timestamp":1759882513707,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MCT - 103817"],"award-info":[{"award-number":["MCT - 103817"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"InnerChange Foundation"},{"name":"Providence Health Care Research Institute"},{"name":"St. Paul\u2019s Hospital Foundation"},{"name":"Vancouver Coastal Health"},{"name":"Michael Smith Foundation for Health Research Career Award"},{"DOI":"10.13039\/501100000024","name":"Canada Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"New Investigator Award"},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CIHR Doctoral Research Awards"},{"name":"Killam Doctoral Scholarship"},{"name":"University of British Columbia\u2019s Public Scholars Initiative"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.drugalcdep.2020.108333","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T03:01:17Z","timestamp":1601607677000},"page":"108333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach"],"prefix":"10.1016","volume":"218","author":[{"given":"Heather","family":"Palis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Guh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Brissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin T.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.drugalcdep.2020.108333_bib0005","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0924-977X(10)70001-8","article-title":"Heroin-assisted treatment in the Netherlands: history, findings, and international context","volume":"20","author":"Blanken","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0010","article-title":"Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence","author":"Oviedo-Joekes","year":"2017","journal-title":"Drug Alcohol Rev."},{"issue":"9729","key":"10.1016\/j.drugalcdep.2020.108333_bib0015","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","article-title":"Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial","volume":"375","author":"Strang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2017.05.044","article-title":"The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada","volume":"48","author":"Franklyn","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(09)61420-3","article-title":"Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study","author":"Marsden","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jsat.2019.03.012","article-title":"Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods","author":"Oviedo-Joekes","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108333_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","article-title":"Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger","volume":"207","author":"Strang","year":"2015","journal-title":"Br. J. Psychiatry"},{"issue":"7410","key":"10.1016\/j.drugalcdep.2020.108333_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","article-title":"Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials","volume":"327","author":"van den Brink","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.drugalcdep.2020.108333_bib0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF01318402","article-title":"Decreasing intravenous cocaine use in opiate users treated with prescribed heroin","volume":"47","author":"Blattler","year":"2002","journal-title":"Soz. Praventivmed."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12954-016-0100-7","article-title":"Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study)","volume":"13","author":"Roux","year":"2016","journal-title":"Harm Reduct. J."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108333_bib0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1521-0391.2010.00049.x","article-title":"Implication of gender differences in heroin-assisted treatment: results from the German randomized controlled trial","volume":"19","author":"Eiroa-Orosa","year":"2010","journal-title":"Am. J. Addict."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0070","first-page":"1015","article-title":"History of treatment access and drug use among participants in a trial testing injectable opioids under supervision for long-term heroin injectors","volume":"3","author":"Oviedo-Joekes","year":"2015","journal-title":"J. Addict. Med. Ther."},{"year":"2016","series-title":"Study to Assess Longer-term Opioid Medication Effectiveness: Double-blind, Non-inferiority Randomized Controlled Trial of Hydromorphone and Diacetylmorphine for the Treatment of Long Term Opioid Dependency","author":"Oviedo-Joekes","key":"10.1016\/j.drugalcdep.2020.108333_bib0075"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0080","first-page":"73","article-title":"Feasibility of applying the life history calendar in a population of chronic opioid users to identify patterns of drug use and addiction treatment","volume":"8","author":"Fikowski","year":"2014","journal-title":"Subst. Abuse"},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108333_bib0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11135-007-9129-8","article-title":"Applications of calendar instruments in social surveys: a review","volume":"43","author":"Glasner","year":"2009","journal-title":"Qual. Quant."},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108333_bib0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10550490500528316","article-title":"The Addiction Severity Index at 25: origins, contributions and transitions","volume":"15","author":"McLellan","year":"2006","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"issue":"12","key":"10.1016\/j.drugalcdep.2020.108333_bib0100","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1046\/j.1360-0443.1998.9312185711.x","article-title":"The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome","volume":"93","author":"Marsden","year":"1998","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108333_bib0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drugalcdep.2005.08.012","article-title":"Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population","volume":"82","author":"van der Zanden","year":"2006","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108333_bib0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09595239600186001","article-title":"Reliability and validity of the Opiate Treatment Index among a sample of opioid users in the United Kingdom","volume":"15","author":"Adelekan","year":"1996","journal-title":"Drug Alcohol Rev."},{"year":"2002","series-title":"Multilevel Analysis: Techniques and Applications","author":"Hox","key":"10.1016\/j.drugalcdep.2020.108333_bib0115"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0120","series-title":"Multilevel Models Project","article-title":"A user\u2019s Guide to MlwiN","author":"Rasbash","year":"2000"},{"year":"2003","series-title":"Multilevel Statistical Models","author":"Goldstein","key":"10.1016\/j.drugalcdep.2020.108333_bib0125"},{"year":"2014","series-title":"Multilevel and SEM Approaches to Growth Curve Modeling","author":"Hox","key":"10.1016\/j.drugalcdep.2020.108333_bib0130"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0135","series-title":"Sociological Methodology","first-page":"111","article-title":"Bayesian model selection in social research","author":"Raftery","year":"1995"},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108333_bib0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/15248371003699969","article-title":"Twelve frequently asked questions about growth curve modeling","volume":"11","author":"Curran","year":"2010","journal-title":"J. Cogn. Dev."},{"year":"2002","series-title":"Hierarchical Linear Models: Applications and Data Analysis Methods","author":"Raudenbush","key":"10.1016\/j.drugalcdep.2020.108333_bib0145"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.csda.2003.08.006","article-title":"The influence of violations of assumptions on multilevel parameter estimates and their standard errors","volume":"46","author":"Maas","year":"2003","journal-title":"Comput. Stat. Data Anal."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0155","series-title":"The SAGE Handbook of Multilevel Modeling","article-title":"Robust methods for multilevel analysis","author":"Hox","year":"2016"},{"year":"2017","series-title":"Stata Statistical Software","author":"StataCorp","key":"10.1016\/j.drugalcdep.2020.108333_bib0160"},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108333_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/00952990.2011.596980","article-title":"Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials","volume":"37","author":"Nunes","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"2-3","key":"10.1016\/j.drugalcdep.2020.108333_bib0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.drugalcdep.2007.02.007","article-title":"The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program","volume":"89","author":"Raffa","year":"2007","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108333_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0180","article-title":"Evaluation of a low-threshold\/high-tolerance methadone maintenance treatment clinic in saint john, New Brunswick, Canada: one year retention rate and illicit drug use","volume":"2013","author":"Christie","year":"2012","journal-title":"J. Addict."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108333_bib0190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1360-0443.2003.00354.x","article-title":"Does retention matter? Treatment duration and improvement in drug use","volume":"98","author":"Zhang","year":"2003","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2010.03.008","article-title":"Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, canada: 1996\u20132006","volume":"39","author":"Nosyk","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","article-title":"Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment","volume":"15","author":"Marchand","year":"2020","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108333_bib0205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/dar.13049","article-title":"Understanding concurrent stimulant use among people on methadone: a qualitative study","volume":"39","author":"McNeil","year":"2020","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0210","doi-asserted-by":"crossref","DOI":"10.1111\/dar.13117","article-title":"Self-managing illicit stimulant use: a qualitative study with patients receiving injectable opioid agonist treatment","author":"Palis","year":"2020","journal-title":"Drug Alcohol Rev."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108333_bib0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/16066359.2015.1017570","article-title":"Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment","volume":"23","author":"Van Horn","year":"2015","journal-title":"Addict. Res. Theory"},{"issue":"8","key":"10.1016\/j.drugalcdep.2020.108333_bib0220","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3109\/10826084.2011.552931","article-title":"Shared decision-making: increases autonomy in substance-dependent patients","volume":"46","author":"Joosten","year":"2011","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","article-title":"Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review","volume":"14","author":"Marchand","year":"2019","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-244X-11-135","article-title":"Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack-cocaine dependence in the Netherlands","volume":"11","author":"Nuijten","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0235","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000631","article-title":"Physician communication in injectable opioid agonist treatment: collecting patient ratings with the communication assessment tool","author":"Palis","year":"2020","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108333_bib0240","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pec.2014.12.003","article-title":"A mixed methods study of patient-provider communication about opioid analgesics","volume":"98","author":"Hughes","year":"2015","journal-title":"Patient Educ. Couns."},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108333_bib0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ACM.0000000000001294","article-title":"Structural vulnerability: operationalizing the concept to address health disparities in clinical care","volume":"92","author":"Bourgois","year":"2016","journal-title":"Acad. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1022565524508","article-title":"HIV risk reduction among African-American women who inject drugs: a randomized controlled trial","volume":"7","author":"Sterk","year":"2003","journal-title":"AIDS Behav."},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108333_bib0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1037\/1064-1297.15.2.165","article-title":"Risk factors in the relationship between gender and crack\/cocaine","volume":"15","author":"Lejuez","year":"2007","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108333_bib0260","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.drugpo.2009.12.008","article-title":"Women's health and use of crack cocaine in context: structural and \u2018everyday\u2019violence","volume":"21","author":"Bungay","year":"2010","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1940-0640-9-21","article-title":"A chance to stop and breathe: participants\u2019 experiences in the North American Opiate Medication Initiative clinical trial","volume":"9","author":"Oviedo-Joekes","year":"2014","journal-title":"Addict. Sci. Clin. Pract."},{"year":"2015","series-title":"The National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","author":"Kampman","key":"10.1016\/j.drugalcdep.2020.108333_bib0270"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0275","first-page":"9","article-title":"Psychostimulant drugs for cocaine dependence","author":"Castells","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0280","first-page":"2233","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis","volume":"Vol. 237","author":"Tardelli","year":"2020"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0285","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12888-016-1141-x","article-title":"Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence","volume":"16","author":"Ezard","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0290","doi-asserted-by":"crossref","DOI":"10.1111\/dar.13126","article-title":"Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: a gender-based analysis","author":"Bach","year":"2020","journal-title":"Drug Alcohol Rev."},{"year":"2020","series-title":"Canadian Drug Summary: Methamphetamine","author":"Canadian Centre on Substance Use and Addiction","key":"10.1016\/j.drugalcdep.2020.108333_bib0295"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: the surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend."},{"year":"2019","series-title":"Responding to British Columbia\u2019 s Public Health Emergency","author":"British Columbia Ministry of Mental Health and Addictions","key":"10.1016\/j.drugalcdep.2020.108333_bib0305"},{"issue":"12","key":"10.1016\/j.drugalcdep.2020.108333_bib0310","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1360-0443.2005.01225.x","article-title":"Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence","volume":"100","author":"Paterson","year":"2005","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108333_bib0315","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/jat\/30.6.390","article-title":"Screening for illicit heroin use in patients in a heroin-assisted treatment program","volume":"30","author":"Rook","year":"2006","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12954-019-0339-x","article-title":"Using life course charts to assess and compare trajectories of amphetamine type stimulant consumption in different user groups: a cross-sectional study","volume":"17","author":"Martens","year":"2020","journal-title":"Harm Reduct. J."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108333_bib0325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/add.14434","article-title":"Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature","volume":"114","author":"O\u2019Donnell","year":"2019","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.drugalcdep.2020.108333_bib0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029476","article-title":"Understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol","volume":"9","author":"Rosenkranz","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0335","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.addbeh.2018.08.042","article-title":"Sociodemographic, neighborhood, psychosocial, and substance use correlates of cocaine use among Black adults: findings from a pooled analysis of national data","volume":"88","author":"Nicholson","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2020.108333_bib0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.addbeh.2019.04.030","article-title":"The chippers, the quitters, and the highly symptomatic: a 12-month longitudinal study of DSM-5 opioid- and cocaine-use problems in a community sample","volume":"96","author":"Stull","year":"2019","journal-title":"Addict. Behav."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620304981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620304981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:08:48Z","timestamp":1759828128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620304981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"alternative-id":["S0376871620304981"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108333","relation":{},"ISSN":["0376-8716"],"issn-type":[{"type":"print","value":"0376-8716"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108333"}}